Onco-Innovations Scales Up PNKP Inhibitor Technology with Dalton Pharma Services

Onco-Innovations Limited has moved to a new phase of process development for its PNKP inhibitor technology with Dalton Pharma Services. This phase includes the expanded scale-up of precursor A83 and a two-kilogram non-GMP synthesis of A83B4C63, supporting IND-enabling studies. The progress aims to refine processes and prepare for future GMP production.

The initiative involves significant material production for formulation development and analytical activities in line with ICH guidelines. Dalton’s facility in Toronto will oversee this work, using pilot-scale equipment and protocols to ensure process reliability.

Additionally, Onco-Innovations extended its market awareness contract with MCS Market Communication Service GmbH. The extension includes a €210,000 investment for enhanced corporate communications, funded partly by a prior engagement refund.